



Early-stage and advanced-stage patients differ significantly in terms of tumor burden, organ reserve, duration of treatment exposure, timing of surgery, and the windows for AE monitoring and reporting. Consequently, perioperative patient counseling, monitoring strategies, and clinical trial designs should—whenever possible—utilize safety estimates specific to the treatment setting.